FOLH1 and neoplasm: Reducing GCPII expression through genetic alterations or pharmacological inhibition of glutamate carboxypeptidase II (GCPII) leads to reductions in glutamate concentration and tumor growth, which are enhanced by targeting GCPII in combination with glutaminase inhibition [257].